SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Vor Biopharma Inc. (VOR) News

Follow Vor Biopharma Inc. (VOR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol VOR Asset equity Sector Markets 90 days 12 Last 19.18 Updated Nov 05, 2026, 06:27 PM UTC Open live news feed Open VOR chart & news
L Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: FMR LLC Filed on: November 5, 20 EQUITY | Nov 05, 2026, 06:27 PM UTC M VOR Reports Fiscal Q3 Net Loss VOR reported a fiscal 2026 third-quarter net loss attributable to shareholders, up 84.74% year over year. Basic earnings per share were negative. EQUITY | Nov 02, 2026, 10:21 AM UTC L Vor Bio Reports 48-Week gMG Data: 42% Reached MSE Vor Bio reported post hoc 48-week data from a China Phase 3 gMG study of telitacicept: 42% reached minimal symptom expression at any time; >94% had ≥5-point MG-ADL improvement. Most MSE events were sustained at the next GEOPOLITICS | Sep 29, 2026, 12:09 PM UTC L Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 4842% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the NEWS | Sep 29, 2026, 12:09 PM UTC M VOR advances Phase III Telitacicept trials for myasthenia gravis, Sjögren’s VOR says Telitacicept, a BAFF-APRIL inhibitor, is advancing in Phase III trials for myasthenia gravis and Sjögren’s, citing strong early enrollment and a differentiated B-cell targeting mechanism. Top-line MG data is ant EQUITY | Sep 09, 2026, 05:06 PM UTC L VOR trial update highlights late-stage progress for Telitacicept Telitacicept is advancing in late-stage trials for myasthenia gravis and Sjögren's disease, with differentiation tied to its dual BAFF-APRIL mechanism and robust safety data from China. GEOPOLITICS | Sep 09, 2026, 04:30 PM UTC M VOR completes Phase III MG trial enrollment; global readout set for 2027 VOR says Phase III MG trial enrollment is completed. A key global readout is expected in 2027, alongside plans for an ocular MG study, with management citing China data on efficacy and durability. GEOPOLITICS | Sep 08, 2026, 02:01 PM UTC M VOR Phase III MG enrollment complete; key readout eyed for early 2027 VOR says enrollment in its Phase III MG trial is complete, with a key readout expected in early 2027. The company also plans an ocular MG study and enhanced dosing convenience. EQUITY | Sep 08, 2026, 01:27 PM UTC M VOR completes Phase III telitacicept enrollment; key readout set for early 2027 VOR says enrollment is complete for its Phase III telitacicept MG trial, with a key readout expected in early 2027. The company is expanding into ocular MG and Sjögren’s, highlighting a dual BAFF/APRIL mechanism. EQUITY | Sep 08, 2026, 01:10 PM UTC M VOR completes Phase 3 UPSTREAM MG enrollment, expands telitacicept to ocular MG VOR says it completed enrollment in its global Phase 3 UPSTREAM MG trial and expanded its telitacicept global franchise into ocular myasthenia gravis. EQUITY | Sep 08, 2026, 11:00 AM UTC L Vor Bio reports inducement grant under Nasdaq Rule 5635(c)(4) Vor Bio reports an inducement grant under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 04, 2026, 08:05 PM UTC L VOR - Vor Bio To Participate in Upcoming September Conferences VOR - Vor Bio To Participate in Upcoming September Conferences EQUITY | Sep 01, 2026, 12:02 PM UTC L Vor Biopharma Q2 Adj. EPS Misses Estimate Vor Biopharma reports Q2 adjusted EPS of $(0.80), missing the $(0.70) estimate EARNINGS | Aug 11, 2026, 09:30 PM UTC L Vor Bio Reports Inducement Grant Vor Bio grants inducement award EQUITY | Aug 03, 2026, 08:30 PM UTC